Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966185 | 0.80 | MEN1 (0.42) | MEN1KMT2ANTRK1ALDH1A1AHR | |
| SCHEMBL10997608 | 0.78 | MEN1 (0.41) | MEN1KMT2AMAPK1NTRK1ALDH1A1 | |
| SCHEMBL1184146 | 0.78 | KMT2A (0.58) | MEN1KMT2ANTRK1ALDH1A1AHR | |
| SCHEMBL19725082 | 0.78 | MEN1 (0.49) | MEN1KMT2AMAPK1NTRK1ALDH1A1 | |
| SCHEMBL4775824 | 0.78 | MEN1 (0.41) | MEN1KMT2AMAPK1NTRK1ALDH1A1 | |
| SCHEMBL31544394 | 0.78 | MEN1 (0.41) | MEN1KMT2AMAPK1NTRK1ALDH1A1 | |
| SCHEMBL16083961 | 0.75 | MEN1 (0.39) | MEN1KMT2AMAPK1NTRK1ALDH1A1 | |
| SCHEMBL170064 | 0.75 | KDM4E (0.44) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL17156365 | 0.75 | MEN1 (0.42) | MEN1KMT2ANTRK1ALDH1A1MAPT | |
| SCHEMBL46639 | 0.74 | MEN1 (0.53) | MEN1KMT2ANTRK1ALDH1A1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101747283-B | Method for preparing 4,6 - dimethoxy -2 - methanesulfonyl pyrimidine | SHENYANG RES INST CHEMICAL IND | 2011-06-08 | — | — | CN | claimed |
| CN-101747283-A | Method for preparing 4,6 - dimethoxy -2 - methanesulfonyl pyrimidine | SHENYANG RES INST CHEMICAL IND | 2010-06-23 | — | — | CN | claimed |
| CN-109851565-A | A kind of preparation method of the chloro- 2- methylthiopyrimidine of 4,6- bis- | 苏州华诺医药有限公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-105026376-B | Process for the preparation of bispyribac-sodium and intermediates thereof | 加尔达化学有限公司 | 2018-05-11 | — | — | CN | disclosed |
| CN-104703990-B | Macrocyclic purines for the treatment of viral infections | 爱尔兰詹森科学公司 | 2017-10-13 | — | — | CN | disclosed |
| CN-101747283-B | Method for preparing 4,6 - dimethoxy -2 - methanesulfonyl pyrimidine | SHENYANG RES INST CHEMICAL IND | 2011-06-08 | — | — | CN | disclosed |
| CN-101747283-A | Method for preparing 4,6 - dimethoxy -2 - methanesulfonyl pyrimidine | SHENYANG RES INST CHEMICAL IND | 2010-06-23 | — | — | CN | disclosed |
| US-20100008874-A1 | SUBSTITUTED PYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS EFFECTIVE ABSORBENTS OF UV IRRADIATION | YISSUM RESEARCH DEVELOPMENT COMPANY (IL) | 2010-01-14 | — | — | US | disclosed |
| CN-100482664-C | 1,5-disubstituted-3,4-dihydro-1H-pyrimido [4,5-D] pyrimidi-2-one compounds and their use in treating CSBP/P38 kinase mediated diseases | SMITHKLINE BEECHAM CORP (US) | 2009-04-29 | — | — | CN | disclosed |
| CN-1422273-A | 1,5-disubstituted-3,4-dihydro-1H-pyrimido [4,5-D] pyrimidi-2-one compounds and their use in treating CSBP/P38 kinase mediated diseases | SMITHKLINE BEECHAM CORP (US) | 2003-06-04 | — | — | CN | disclosed |
| CN-1396158-A | Process for synthesizing 4,6-dimethoxy-2-methiopyrimidine | UNIV ZHEJIANG POLYTECHNIC (CN) | 2003-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008874-A1 | SUBSTITUTED PYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS EFFECTIVE ABSORBENTS OF UV IRRADIATION | UNG, UMPS, TYMP | MEN1 3516/4885KMT2A 3462/4885MAPK1 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.